Interestingly, our data suggest that BTF3 overexpression sensitizes prostate cancer cells to the DNA damaging agent cisplatin and may serve as a potential predictive marker for the selection of patient for platinum-based treatment. The gene discussed is BTF3; the disease is prostate carcinoma.